All stakeholders, including leaders across industry and health authorities, agree that finding answers to market access is critical to delivering breakthrough medicines to patients. Unfortunately, policies and practices do not always marry up.

This meeting will bring together professionals working with regulatory and value strategies. HTA bodies and regulators are breaking down silos, facilitating access to new promising medicines and increasing efficiencies in assessment processes. Similarly, R&D processes need to adapt to generate the appropriate evidence for registration and reimbursement that should allow patients’ timely access to innovative and promising drugs.

Bringing together policy makers, developers, and the patients as end users, to keep you ahead of the game with practical solutions.

DIA shares insights in advance of this conference:

Hear a preview of programme committee member Solange Corriol-Rohou’s perspective on evidence generation throughout the life-cycle to support Medicines Adaptive Pathways to Patients (MAPPs) in the IMI project ADAPT SMART Webinar: ADAPT SMART “Putting Stakeholders at the Centre”


Day 1 25 Oct 2017

8:00 AM Registration and Welcome Coffee
8:30 AM Keynote Speech
9:00 AM Session 1: Different Perspectives on Unmet Medical Need
10:30 AM Coffee Break
11:00 AM Session 2: Adaptive Pathways and Innovative Medicines Development for Improved Access
12:30 PM Lunch
2:00 PM Session 3: Early Dialogue Between Regulators and HTA (and Payers & Patients)
3:30 PM Coffee Break
4:00 PM Session 4: Patient’s Role in the Regulatory and HTA Process
5:30 PM — 6:30 PM Networking Reception

Day 2 26 Oct 2017

8:00 AM Registration & Coffee
9:00 AM  Session 5: Evolution of Product Development to Respond to the Future Needs
10:30 AM Coffee Break
11:00 AM Session 6: Use of Real-World Evidence to Support Access
12:30 PM Lunch
2:00 PM — 3:30 PM Session 7: Relative Efficacy versus Relative Effectiveness – the Future